Trial Profile

RITUXIMAB IN LIFE THREATENING THERAPY RESISTANT PROGRESSIVE INTERSTITIAL PNEUMONITIS

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary)
Indications Pneumonitis
Focus Therapeutic Use
Acronyms RITUX-IP

Most Recent Events

01 Jun 2023 Results (n=21) elucidating if imaging of CD20-positive cells in the lungs allows prediction of the response to anti-CD20 treatment published in the European Journal of Nuclear Medicine and Molecular Imaging
30 May 2018 Status changed from active, no longer recruiting to completed.
25 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com